Introduction

Manganese is an essential trace mineral that plays a critical role in human health. Though required in only small amounts, this nutrient acts as a cofactor for numerous enzymes that regulate metabolism, antioxidant defenses, and blood glucose control. In the context of diabetes, understanding how manganese influences enzymatic pathways offers valuable insights into both prevention and management strategies. This article explores the biochemical functions of manganese, its specific role in enzymes relevant to diabetes, dietary sources, supplementation considerations, and the clinical implications of maintaining optimal manganese status.

The Biochemical Role of Manganese in Metabolism

Manganese is a transition metal that exists in multiple oxidation states, with Mn²⁺ being the most biologically relevant form. It serves as a cofactor for several classes of enzymes, including oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. In metabolic pathways, manganese-dependent enzymes are particularly important for carbohydrate, lipid, and amino acid metabolism.

Manganese as an Enzyme Cofactor

Manganese ions bind to enzyme active sites, facilitating substrate binding, electron transfer, or structural stabilization. Unlike other metals such as magnesium or zinc, manganese can adopt different coordination geometries, enabling it to participate in a wide range of catalytic reactions. This versatility is why manganese is indispensable for processes like gluconeogenesis, the urea cycle, and antioxidant protection. The binding affinity of manganese for specific enzymes is often modulated by the local pH and redox environment, a factor that becomes particularly relevant in the hyperglycemic and acidotic conditions seen in poorly controlled diabetes.

Key Manganese-Dependent Enzymes Relevant to Diabetes

  • Pyruvate carboxylase: This mitochondrial enzyme catalyzes the conversion of pyruvate to oxaloacetate, a key step in gluconeogenesis. Manganese is required for the enzyme’s activity, and deficiency can impair glucose production from non‑carbohydrate precursors, disrupting blood sugar regulation. In diabetes, however, pyruvate carboxylase is often upregulated due to elevated glucagon and cortisol, contributing to fasting hyperglycemia. The dual role of manganese—both as an essential activator and a potential limiting factor—makes this enzyme a target for nutritional modulation.
  • Arginase: Manganese activates arginase, which hydrolyzes arginine to ornithine and urea in the urea cycle. In diabetes, elevated ammonia levels can occur due to altered protein metabolism, and adequate arginase activity helps prevent ammonia toxicity. Additionally, arginase competes with nitric oxide synthase for arginine, so changes in manganese status may influence vascular tone and endothelial function, both of which are compromised in diabetic vasculopathy.
  • Manganese superoxide dismutase (MnSOD): This mitochondrial antioxidant enzyme converts superoxide radicals into hydrogen peroxide and oxygen, protecting cells from oxidative damage. Oxidative stress is a hallmark of diabetes and its complications, making MnSOD a critical defense mechanism. The enzyme’s activity is regulated by manganese availability and by transcription factors such as FOXO3a and NRF2, which are often dysregulated in diabetes. Compromised MnSOD function directly accelerates mitochondrial injury and insulin resistance.
  • Glutamine synthetase: Manganese is a cofactor for glutamine synthetase, which synthesizes glutamine from glutamate and ammonia. Glutamine plays roles in immune function, intestinal health, and nitrogen balance, all of which can be compromised in diabetes. In particular, glutamine supports pancreatic beta‑cell viability and may enhance insulin secretion via glucagon‑like peptide‑1 (GLP‑1) pathways, though this requires further human investigation.
  • Phosphoenolpyruvate carboxykinase (PEPCK): While PEPCK is often regulated by other metals, manganese can influence its activity in some contexts, further linking manganese to gluconeogenic control. In animal models, manganese supplementation has been shown to reduce PEPCK expression and blunt glucose output, but human data remain sparse and inconsistent.

Manganese and Glucose Homeostasis

Glucose homeostasis depends on the precise coordination of insulin secretion, glucose uptake, and hepatic glucose production. Manganese contributes to each of these processes through its enzyme cofactor functions, as well as through direct effects on cell signaling and ion channel modulation.

Gluconeogenesis and Glycolysis Regulation

Pyruvate carboxylase, a manganese-dependent enzyme, is a rate‑limiting step for gluconeogenesis in the liver and kidneys. In diabetes, excessive gluconeogenesis contributes to fasting hyperglycemia. Manganese deficiency may impair this enzyme, but chronic overactivation due to other hormonal signals (e.g., glucagon, cortisol) also occurs. Understanding manganese’s role helps researchers explore whether nutritional modulation can fine‑tune this pathway. For instance, some evidence indicates that manganese can allosterically inhibit phosphofructokinase, a glycolytic enzyme, thereby shifting flux toward gluconeogenesis when manganese levels are high. This complexity highlights the need for precise homeostatic control.

Additionally, manganese influences enzymes in glycolysis, such as enolase and pyruvate kinase, although these are more commonly magnesium-dependent. The interplay between manganese and other divalent cations affects overall glucose flux. In tissues with high metabolic rates like skeletal muscle, manganese’s competition with magnesium for binding sites on glycolytic enzymes may become significant during periods of rapid glucose utilization.

Insulin Secretion and Sensitivity

Manganese is involved in insulin synthesis and secretion. Studies show that manganese accumulates in pancreatic beta‑cells and is necessary for normal glucose‑stimulated insulin release. Mechanistically, manganese may activate calcium channels or influence exocytosis. Furthermore, some research suggests that manganese supplementation improves insulin sensitivity in animal models, possibly through reduced oxidative stress and enhanced mitochondrial function. In isolated islets, manganese has been shown to amplify glucose‑induced insulin secretion in a dose‑dependent manner, an effect that is partially mediated by extracellular signal‑regulated kinase (ERK) signaling.

However, human studies are limited. A 2017 cross‑sectional study in Biological Trace Element Research found that serum manganese levels were inversely associated with insulin resistance in Chinese adults, indicating that adequate manganese status may support metabolic health. (Source: Biol Trace Elem Res, 2017) More recently, a 2021 study in Diabetes Care reported that dietary manganese intake was positively associated with insulin sensitivity in a cohort of overweight adults, but the authors noted that the association disappeared after adjusting for confounding factors like fiber intake. (Source: Diabetes Care, 2021)

Manganese Transport and Cellular Uptake

The regulation of manganese within beta‑cells depends on specific transport proteins, particularly the divalent metal transporter 1 (DMT1) and the zinc transporter ZnT8. Polymorphisms in these transporters may affect intracellular manganese levels and influence diabetes risk. For example, common variants in SLC30A8 (encoding ZnT8) have been linked to type 2 diabetes susceptibility, and these variants also alter manganese handling in islets. Understanding the genetics of manganese transport could lead to personalized nutritional recommendations.

Manganese and Oxidative Stress in Diabetes

Oxidative stress arises from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses. Hyperglycemia enhances ROS generation through multiple pathways: increased mitochondrial electron transport leak, activation of protein kinase C (PKC), and elevated advanced glycation end‑products (AGEs). The resulting damage to proteins, lipids, and DNA contributes to diabetic complications such as nephropathy, neuropathy, and retinopathy.

MnSOD and Mitochondrial Protection

MnSOD is the primary mitochondrial antioxidant enzyme. Its manganese‑dependent activity neutralizes superoxide radicals produced during oxidative phosphorylation. In diabetes, mitochondrial dysfunction increases superoxide leakage, and reduced MnSOD activity exacerbates cellular damage. Animal studies show that overexpression of MnSOD protects against diabetic kidney disease and cardiomyopathy. Conversely, manganese deficiency lowers MnSOD activity, raising oxidative stress. Some human studies report lower MnSOD activity in diabetic patients, although it is unclear whether this reflects deficiency or post‑translational modifications such as acetylation or phosphorylation that inactivate the enzyme.

Ensuring adequate manganese intake may help maintain MnSOD function, but excess manganese can also be pro‑oxidant, so balance is key. The manganese‑dependent activation of MnSOD requires precise metalation within the mitochondria; disruption of this process by iron overload or oxidative stress itself can create a vicious cycle of increasing ROS and declining antioxidant capacity.

Other Antioxidant Roles

Manganese also acts as a cofactor for other antioxidant enzymes, including catalase (though primarily heme‑based) and certain peroxidases. Additionally, manganese can directly scavenge free radicals under some conditions, particularly the superoxide anion. This direct antioxidant activity is most relevant in tissues with high manganese concentrations, such as the liver and pancreas. However, at supraphysiological levels, manganese can participate in Fenton‑like reactions, generating hydroxyl radicals. This dual role as both an essential nutrient and a potential pro‑oxidant at high levels underscores the importance of maintaining physiological concentrations.

Manganese Deficiency and Diabetes Risk

Manganese deficiency is rare in humans but can occur with poor dietary intake, malabsorption disorders (e.g., Crohn’s disease, celiac disease, or after bariatric surgery), or increased losses (e.g., through hemodialysis). Several lines of evidence link low manganese status to impaired glucose tolerance and increased diabetes risk.

Epidemiological Evidence

Population studies have found that individuals with type 2 diabetes often have lower serum or plasma manganese levels compared to healthy controls. A meta‑analysis of 15 case‑control studies reported significantly lower manganese levels in diabetic subjects (SMD: –0.86, 95% CI –1.33 to –0.38). However, results vary by ethnicity, sex, and glycemic control. (Source: Nutrients, 2020) Some studies have noted that the inverse association between manganese and diabetes is stronger in women than in men, possibly due to hormonal differences in manganese handling.

Longitudinal data are still limited. The Nurses’ Health Study reported no significant association between dietary manganese intake and incident type 2 diabetes, but toenail manganese, a long‑term biomarker, was inversely related to diabetes risk. These inconsistencies highlight the need for standardized measurements and prospective cohort designs.

Mechanisms Linking Deficiency to Dysglycemia

Manganese deficiency may contribute to diabetes through several mechanisms:

  • Impaired gluconeogenesis and glycolysis due to reduced pyruvate carboxylase activity.
  • Decreased insulin secretion from beta‑cells as a result of defective exocytosis and calcium signaling.
  • Heightened oxidative stress from reduced MnSOD activity, leading to mitochondrial dysfunction and insulin resistance.
  • Altered lipid metabolism, as manganese‑dependent enzymes like acetyl‑CoA carboxylase (though primarily biotin‑dependent) also play roles in fatty acid synthesis and oxidation.
  • Disrupted pancreatic islet development: animal models of manganese deficiency show reduced beta‑cell mass, which may be irreversible if occurring during critical growth periods.

These connections highlight the potential role of manganese in diabetes etiology, though more prospective studies are needed to establish causality and to determine whether manganese supplementation can reverse or prevent dysglycemia in deficient populations.

Dietary Sources and Bioavailability

Manganese is widely available in plant‑based foods, but its bioavailability depends on food matrix and other dietary factors. Understanding these nuances is essential for optimizing intake without relying on supplements.

Food Sources

Rich sources of manganese include:

  • Nuts (especially hazelnuts, pecans, and almonds)
  • Seeds (pumpkin seeds, sesame seeds, flaxseeds)
  • Whole grains (brown rice, oats, quinoa, barley)
  • Legumes (soybeans, chickpeas, lentils)
  • Leafy green vegetables (spinach, kale, Swiss chard)
  • Tea (black and green teas are high in manganese; a cup of black tea can provide 0.5–1.5 mg)
  • Pineapple, blackberries, and other fruits

The manganese content of foods can vary based on soil quality and processing. Refined grains lose significant manganese—for example, white rice contains only about 20% of the manganese found in brown rice. Therefore, whole foods are strongly preferred for maintaining manganese status.

Factors Affecting Absorption

Manganese absorption occurs mainly in the small intestine via DMT1 and other transporters, and is influenced by:

  • Iron status: High iron intake or iron overload can compete with manganese for DMT1 absorption, potentially lowering manganese levels. Individuals with hemochromatosis or those taking high‑dose iron supplements should be aware of this interaction.
  • Calcium and phosphorus: High intakes of these minerals may reduce manganese absorption, possibly through competition for binding sites or through formation of insoluble complexes.
  • Phytate and oxalate: Found in some plant foods, these compounds can bind manganese and decrease bioavailability. However, fermentation and sprouting can reduce phytate content and improve absorption.
  • Gastric acidity: Adequate stomach acid aids absorption; conditions like achlorhydria or the use of proton pump inhibitors may impair it.

These interactions mean that simply eating manganese‑rich foods does not guarantee optimal status, especially in individuals with restrictive diets, digestive issues, or concurrent mineral imbalances.

Supplementation Considerations

While supplementation may be considered for those at risk of deficiency, caution is warranted because excess manganese can be toxic. The narrow therapeutic window between adequacy and toxicity makes this one of the more challenging trace elements to manage.

The National Academies of Sciences, Engineering, and Medicine has established an Adequate Intake (AI) for manganese:

  • Men (19+ years): 2.3 mg/day
  • Women (19+ years): 1.8 mg/day
  • Pregnancy: 2.0 mg/day
  • Lactation: 2.6 mg/day

The Tolerable Upper Intake Level for adults is 11 mg/day from supplements and food combined. Chronic excess manganese, often from occupational exposure (e.g., welding) or excessive supplementation, can cause neurological symptoms similar to Parkinson’s disease, known as manganism. (Source: NIH Office of Dietary Supplements) Symptoms of manganese toxicity include tremor, dystonia, and cognitive decline, and they may be irreversible.

Interactions with Other Minerals

Manganese supplementation must be balanced with iron, calcium, and zinc status. For example, high‑dose calcium supplements taken with manganese may reduce absorption. In diabetes management, patients often take multiple supplements—such as chromium, magnesium, and zinc—so it is important to avoid overloading on any single mineral. Additionally, manganese competes with zinc for absorption, and high zinc intakes can exacerbate manganese deficiency in vulnerable populations.

Diabetics with chronic kidney disease may be at increased risk of manganese accumulation due to impaired excretion. Therefore, supplementation should only be initiated under medical supervision with appropriate laboratory monitoring, including serum or whole blood manganese levels.

Clinical Implications for Diabetes Management

Integrating manganese considerations into diabetes care requires a practical, evidence‑informed approach. While routine screening for manganese deficiency is not currently recommended, certain patient groups warrant closer attention.

Monitoring Manganese Status

Routine measurement of manganese in clinical practice is not standard, but it may be useful in patients with unexplained metabolic disturbances, those on restrictive diets (e.g., vegan or macrobiotic), patients after bariatric surgery, or those with malabsorptive disorders. Serum or plasma manganese levels, along with whole blood manganese, can indicate status. However, these tests are not always covered by insurance and can be influenced by acute illness or recent meals. Toenail manganese offers a longer‑term biomarker but is less commonly used.

Dietary Strategies for Diabetes Control

Emphasizing a diet rich in whole plant foods naturally supports manganese intake while providing fiber, antioxidants, and other protective nutrients. For example:

  • Include a handful of nuts or seeds daily—for instance, 30 g of almonds provides about 0.6 mg of manganese.
  • Choose whole grains over refined carbohydrates; swapping white rice for brown rice triples manganese intake per serving.
  • Add leafy greens to meals; one cup of cooked spinach contains roughly 0.8 mg.
  • Drink tea moderately (watch added sugars); 2–3 cups of unsweetened tea can contribute up to 1 mg of manganese.

These dietary patterns align with general diabetes guidelines from the American Diabetes Association, which recommend a Mediterranean‑style or DASH diet. (Source: Diabetes Care, 2024) The whole‑food patterns also provide the complementary minerals and phytochemicals that help mitigate the risk of manganese overdose and optimize enzyme function.

Caution with Supplements

Given the potential for toxicity and interactions, manganese supplementation is not recommended for most people with diabetes unless a deficiency is confirmed by laboratory testing. Foods should remain the primary source. If supplementation is deemed necessary—for example, in a patient with documented low manganese and impaired glucose tolerance—a low dose (e.g., 5 mg or less per day) with careful monitoring is advisable. It is also prudent to check iron status and kidney function before initiating manganese supplements.

Conclusion

Manganese is a small but mighty mineral that supports enzymes central to glucose metabolism, antioxidant defense, and overall metabolic health. Its role as a cofactor for pyruvate carboxylase, MnSOD, and arginase underscores its relevance to diabetes pathophysiology. While severe deficiency is uncommon, suboptimal manganese status may worsen glycemic control and increase oxidative stress. Dietary sources rich in whole grains, nuts, seeds, and leafy greens can help maintain adequate intakes without the risks of supplementation. As research continues to clarify the precise relationships between manganese status and diabetes outcomes—including the roles of transport genetics and tissue‑specific bioavailability—clinicians and patients should consider this trace mineral as part of a comprehensive nutritional strategy. Always consult a healthcare provider before making significant changes to supplement regimens, particularly in the presence of chronic disease or multiple mineral supplements.